A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

Researchers at Karolinska Institutet in Stockholm, Sweden, have shown that specific blood biomarkers can predict development of dementia up to 10 years before symptoms appear. But their primary value ...

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...

Doctors are learning more about the wider effects of the injections, from lowering blood pressure to helping people quit ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

Alzheimer's is the most common form of dementia ... which is the active ingredient in Ozempic and Wegovy. Ozempic is not marketed as a weight loss drug and is prescribed to those with type ...

The US is by far the world’s leading funder of biomedical research. But the Trump administration reportedly plans to ask ...

Jamie Mafdali of South Florida was hit with a cancer double-whammy three years ago. Shortly after her mother began treatment ...

from reducing addictive behaviours to lowering the risk of Alzheimer’s disease. Research has found that weight-loss drugs such as Ozempic may help curb addictive behaviours, such as alcohol ...

The state’s largest commercial health insurer will stop covering a popular class of prescription drugs for weight loss, ...

This summary of health news briefs includes reports on how the U.S.-China trade war impacts drug costs, EU approval of ...